Hummel, H., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., . . . Bargou, R. C. (2021). Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy, 13(2), . https://doi.org/10.2217/imt-2020-0256
Chicago-Zitierstil (17. Ausg.)Hummel, Horst-Dieter, et al. "Pasotuxizumab, a BiTE® Immune Therapy for Castration-resistant Prostate Cancer: Phase I, Dose-escalation Study Findings." Immunotherapy 13, no. 2 (2021). https://doi.org/10.2217/imt-2020-0256.
MLA-Zitierstil (9. Ausg.)Hummel, Horst-Dieter, et al. "Pasotuxizumab, a BiTE® Immune Therapy for Castration-resistant Prostate Cancer: Phase I, Dose-escalation Study Findings." Immunotherapy, vol. 13, no. 2, 2021, https://doi.org/10.2217/imt-2020-0256.